Table 1

ALVs escape a systemic CTL response in gp33-Lo tumors.

Type of challenge2 Cell line T cells Tumor outgrowth in experiment no.1 Total
1 23 3 4 53 6 Tumor growth Antigen retained4
Unilateral gp33-Lo - 1/1 - - - - - 1/1 N.D.5
+ 1/1 2/2 1/1 1/1 - - 5/5 N.D.
gp33-Hi - 1/1 - - - - - 1/1 N.D.
+ 0/1 0/2 0/1 0/1 - - 0/5 N.A.5
Bilateral gp33-Lo - - 1/1 1/1 1/1 1/1 2/2 6/6 2/26
gp33-Hi - 1/1 1/1 1/1 1/1 2/2 6/6 N.D.
gp33-Lo + - - 4/4 - 4/4 3/3 11/11 0/77
gp33-Hi - - 0/4 - 0/4 0/3 0/11 N.A.

1Mice bearing two week established tumors received approximately 107 adoptively transferred naive P14 T cells. Tumor outgrowth was assessed after 30 days. 2In unilateral challenges, 2C mice received a single challenge of either 106 gp33-Hi cells or 106 gp33-Lo cells. In bilateral challenges, 2C mice received a challenge of 106 gp33-Lo cells on the left flank and a challenge of 106 gp33-Hi cells on the right flank. 3In experiment 2 and 5, CD8-purified P14 T cells were transferred into 2C x Rag2(-/-) mice indicating that the rejection of gp33-Hi tumors is not due to endogenous CD4+ T cells or B cells in the 2C host. 4The averages of each group are from two independent experiments. 5N.D. = Not done. N.A. = Not applicable. 64OH-TAM treatment induced 67.0 0.6% of the cells above background. The average fold increase above the untreated control was 19.7 10.2. 74OH-TAM treatment induced 4.39 2.1% of the cells above background. The average fold increase above the untreated control was 2.2 0.8.